The association of peripheral neuropathy detected by monofilament testing with risk of falls and fractures in older adults - Hicks CW, Wang D, Daya N, Juraschek SP, Matsushita K, Windham BG, Selvin E.
BACKGROUND: In persons with diabetes, annual screening for peripheral neuropathy (PN) using monofilament testing is the standard of care. However, PN detected by monofilament testing is common in older adults, even in the absence of diabetes. We aimed to a... (Source: SafetyLit)
Source: SafetyLit - March 24, 2023 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Pain Management
Ms. P is a 72-year-old woman who was admitted for rehabilitation after an above-the-knee amputation for a lower-extremity ulcer that did not heal due to associated arterial insufficiency. Her past medical history includes a cerebral vascular event and left hemiparesis, diabetes controlled by diet and oral medication, hypertension, peripheral neuropathy, and arterial insufficiency. (Source: Caring for the Ages)
Source: Caring for the Ages - March 1, 2023 Category: Health Management Authors: Barbara Resnick, Paige Hector Tags: Interdisciplinary Team Case Scenario Source Type: news

What is PAN?
Discussion Vasculitis is an inflammation of the blood vessels. Often, the term implies the arterial vessels, but venous and capillary vessels can be affected. The nomenclature to describe vasculitis and its classification have varied over time. Arterial vessel size is one method and some more common entities include: Small vessel, mainly Granulomatous – granulomatosis with polyangiitis (aka Wegener’s granulomatosis), eosinophilic granulomatosis with polyangiitis (aka Churg Strauss syndrome) Nongranulomatous – Henoch-Schonlein purpura (HSP), microscopic polyangiitis Medium vessel, mainly Childhood sys...
Source: - February 27, 2023 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI ® (cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma
RARITAN, New Jersey, January 27, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Phase 3 CARTITUDE-4 study evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) versus pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd) for the treatment of patients with relapsed and lenalidomide-refractory multiple myeloma met its primary endpoint of significant improvement in progression-free survival (PFS) at the first pre-specified interim analysis. As a result of meeting the primary endpoint, the Independent Data Monitoring Commi...
Source: Johnson and Johnson - January 27, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

FDA Clears Spinal Cord Stimulator for Diabetic Neuropathy FDA Clears Spinal Cord Stimulator for Diabetic Neuropathy
The Food and Drug Administration has approved Abbott ' s Proclaim XR spinal cord stimulation system for the treatment of diabetic peripheral neuropathy, the company announced.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - January 26, 2023 Category: Endocrinology Tags: Neurology & Neurosurgery News Alert Source Type: news

FDA Approves Abbott's Spinal Cord Stimulation for People Living with Painful Diabetic Peripheral Neuropathy
The new indication for Abbott's Proclaim™ XR SCS system provides a non-medication option for people with painful diabetic peripheral neuropathy Spinal cord stimulation is proven to be more effective than conventional medical management in the treatment ... Devices, Neurology, FDA Abbott, spinal cord stimulation, diabetic peripheral neuropathy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 26, 2023 Category: Pharmaceuticals Source Type: news

FDA Approves Abbott's Spinal Cord Stimulation for People Living with Painful Diabetic Peripheral Neuropathy
Source: - January 26, 2023 Category: Pharmaceuticals Source Type: news

Antihypertensives and Dementia; Peripheral Neuropathy Marker; Who Can Get Lecanemab?
(MedPage Today) -- New use of antihypertensive medications that stimulated rather than inhibited type 2 and 4 angiotensin II receptors was linked with lower dementia risk. (JAMA Network Open) Full data about an implanted endovascular brain-computer... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - January 10, 2023 Category: Neurology Source Type: news

Post-acute Sensory Neurological Sequelae in SARS-CoV2 Infection Post-acute Sensory Neurological Sequelae in SARS-CoV2 Infection
This study investigated the incidence and severity of peripheral neuropathy and pain symptoms in patients who tested positive for SARS-CoV-2 infection, both acutely and up to 90 days after testing.Pain (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 14, 2022 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

What to Know About Diabetes and the Risk of Silent Heart Attacks
At first it seemed like a routine call—something the paramedics had dealt with countless times before. A man in his mid-50s was having a heart attack, and his physician had called for emergency support. But when the paramedics arrived, the physician pulled them aside and told them something peculiar: the man had no cardiovascular symptoms whatsoever. The man had come to his doctor’s office because he’d woken early the previous morning sweating and with a sharp pain in his left wrist. These symptoms had quickly subsided and he’d gone back to sleep. Later, after going about his day, he’d visited...
Source: TIME: Health - November 4, 2022 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized healthscienceclimate heart health Source Type: news

Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio
RARITAN, N.J., November 3, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to redefining treatment outcomes in the hematology setting and today announced that abstracts from more than 50 company-sponsored studies, plus more than 20 investigator-initiated studies, will be presented at the American Society of Hematology (ASH) Annual Meeting in New Orleans from December 10-13, 2022. Janssen’s commitment to advancing an innovative portfolio of therapies for healthcare professionals and patients is evidenced through more than 70 presentations that span clinical studies and r...
Source: Johnson and Johnson - November 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Bexion Pharmaceuticals doses first patient in new cancer clinical study
A Northern Kentucky startup developing targeted therapies for cancer has dosed its first patient in a clinical study being held in Cincinnati. Covington-based Bexion Pharmaceuticals, a clinical-stage biopharma company, said Tuesday it dosed its first adult patient in the new study for BXQ-350, its lead drug candidate.   The study, known as RETRO, will assess the potential for BXQ-350 to reduce the intensity and/or duration of chemotherapy-induced peripheral neuropathy, or CIPN, a common side effect… (Source: Health Care News Headlines)
Source: Health Care News Headlines - October 19, 2022 Category: Health Management Authors: Liz Engel Source Type: news

Acute peripheral neuropathy following animal envenomation: a case report and systematic review - Mathis S, Carla L, Duval F, Nadal L, Sol é G, Le Masson G.
Animal envenomation in humans is usually accidental or for defensive purposes. Depending on the venom composition and administration, different reactions can be observed. After reporting the first case of acute polyradiculitis in a 57-year-old healthy male... (Source: SafetyLit)
Source: SafetyLit - October 18, 2022 Category: International Medicine & Public Health Tags: Non-Human Animals and Insects Source Type: news

Extended effects of a wearable sensory prosthesis on gait, balance function and falls after 26 weeks of use in persons with peripheral neuropathy and high fall risk-The walk2Wellness trial - Oddsson LIE, Bisson T, Cohen HS, Iloputaife I, Jacobs L, Kung D, Lipsitz LA, Manor B, McCracken P, Rumsey Y, Wrisley DM, Koehler-McNicholas SR.
BACKGROUND: We recently reported that individuals with impaired plantar sensation and high fall risk due to sensory peripheral neuropathy (PN) improved gait and balance function following 10 weeks of use of Walkasins( ®), a wearable lower limb sensory pros... (Source: SafetyLit)
Source: SafetyLit - October 10, 2022 Category: International Medicine & Public Health Tags: Engineering, Physics, Structural Soundness and Failure Source Type: news

Hand Cooling, Compression Both Effective for Nerve Pain in Breast Cancer
(MedPage Today) -- PARIS -- Hand cooling and compression each cut the risk of high-grade chemotherapy-induced peripheral neuropathy (CIPN) in patients undergoing treatment for primary breast cancer, according to the first prospective trial comparing... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 15, 2022 Category: Hematology Source Type: news